TG Therapeutics Consensus Appears Stale After Recent Downgrades—But Visibility Remains Low

TG Therapeutics reports first-quarter 2026 earnings before the market opens on Monday, May 4, with analysts expecting $0.23 per share on the company's continued commercial ramp of Briumvi. The central question: can TGTX sustain momentum after a volatile earnings track record that has seen massive beats followed by sharp misses? With the stock trading near $34 and analysts projecting 667% year-over-year EPS growth, this report will test whether the company's transition from clinical-stage biotech to commercial powerhouse is on solid footing or still prone to the execution stumbles that have defined recent quarters.

Part 1: Earnings Preview

TG Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for B-cell diseases, with its lead asset Briumvi (ublituximab) approved for relapsing forms of multiple sclerosis in partnership with Biogen. The company also markets Ukoniq for marginal zone lymphoma and chronic lymphocytic leukemia, positioning TGTX at the intersection of neurology and hematology-oncology.

TGTX will report Q1 2026 results before Monday's open, with the Street modeling $0.23 EPS and approximately $198 million in revenue. The most recent quarter (Q4 2025) delivered $0.14 per share, missing estimates of $0.35 by 60%. Compared to the year-ago quarter's $0.03, the consensus implies +667% year-over-year growth—a dramatic acceleration that hinges on Briumvi's commercial trajectory and operational leverage as the launch matures.

Three key themes define this earnings story:

Briumvi Commercial Execution: The multiple sclerosis franchise remains the primary value driver, with investors scrutinizing prescription trends, market share gains against Ocrevus and Kesimpta, and whether the revenue ramp can support the aggressive growth assumptions embedded in estimates. Any commentary on payer dynamics, patient starts, or competitive positioning will be critical.

Profitability Inflection: After Q3's stunning $2.43 EPS beat (driven largely by one-time items) and subsequent misses, the Street is watching whether TGTX can demonstrate sustainable profitability. Gross-to-net adjustments, SG&A discipline, and operating leverage will determine if the company has truly turned the corner or if earnings remain lumpy and unpredictable.

Pipeline Progress and Capital Allocation: With Briumvi established, investors want visibility on lifecycle management opportunities, potential label expansions, and how management plans to deploy cash—whether through R&D reinvestment, business development, or returning capital. Any updates on the ublituximab development roadmap or strategic priorities will shape the growth narrative beyond 2026.

Analysts remain constructive heading into the print. JPMorgan recently reiterated Overweight with a $46 target, citing durable Briumvi demand and improving unit economics. Goldman Sachs holds a Neutral stance at $39, noting valuation reflects much of the near-term upside but acknowledging execution has been solid. The consensus skews bullish, with six Strong Buys against two Holds and one Moderate Sell, reflecting confidence in the commercial story tempered by concerns over earnings volatility and a crowded MS market.

Part 2: Historical Earnings Performance

TGTX's earnings history reveals a company in transition, with results swinging wildly as it scales from clinical-stage losses to commercial profitability. Over the past four quarters, the company has missed estimates three times and beaten once—but that single beat in Q3 2025 was extraordinary, delivering $2.43 versus $0.24 expected for a +913% surprise. Strip out that outlier, and the pattern is one of consistent underperformance: Q4 missed by 60%, Q2 by 47%, and Q1 by 83%.

The Q3 blowout appears to have been driven by non-recurring items rather than sustainable operational strength, as the company immediately reverted to a significant miss the following quarter. This volatility suggests TGTX is still navigating the complexities of commercial-stage operations—managing inventory, gross-to-net deductions, and expense timing—rather than delivering the predictable earnings progression investors typically reward. The year-over-year comparisons are skewed by the company's rapid commercialization: Q1 2025's $0.03 was an early-stage result, making the 667% growth estimate for Q1 2026 more a reflection of the low base than a sustainable run rate.

The trend is clear: TGTX has struggled to meet Street expectations outside of one-time events, with an average miss of roughly 57% when excluding the Q3 anomaly. For Monday's report, investors should approach the $0.23 consensus with caution—the company has yet to prove it can consistently deliver on guidance, and any shortfall could trigger another sharp reset in expectations.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

TGTX typically reports earnings before the market open, meaning Day 0 captures the first full trading session's reaction to results, while Day +1 reflects follow-through or reversal dynamics.

The stock exhibits high volatility around earnings, with an average absolute Day 0 move of 12.28% and intraday range of 14.63%—well above typical biotech peers. Recent reports have been particularly dramatic: the Q1 2025 miss triggered a -13.26% Day 0 drop, while the Q4 2024 beat sparked a +14.39% surge. The Q2 2025 miss produced the largest reaction, a -18.0% Day 0 decline, underscoring how severely the market punishes execution stumbles.

Day +1 moves average 3.44%, suggesting initial reactions tend to stick rather than reverse, though follow-through is less extreme than the Day 0 response. The 7.45% average Day +1 range indicates continued elevated volatility into the second session, likely driven by analyst commentary and institutional repositioning. Investors should brace for a potential double-digit swing on Monday, with the direction hinging entirely on whether TGTX can finally deliver a clean beat—or if another miss extends the pattern of disappointing execution.

Part 2.2: Options Market Expected Move

The options market is pricing an 8.79% expected move through the May 15 expiration, implying a range of $30.86 to $36.81. This sits below the 12.28% average historical Day 0 move, suggesting options traders may be underestimating volatility risk or that recent earnings reactions have been outliers. Given TGTX's track record of double-digit swings, the options market's more conservative stance could present opportunity for volatility buyers—or reflect skepticism that this quarter will deviate from the recent pattern of muted reactions following the Q3 blowout.

Part 3: What Analysts Are Saying

Analysts maintain a bullish stance on TGTX, with the consensus rating at 4.22 out of 5.0—solidly in Buy territory. The breakdown shows six Strong Buys, zero Moderate Buys, two Holds, one Moderate Sell, and zero Strong Sells across nine covering firms. The average price target of $44.57 implies 32% upside from the current $33.85 price, with a wide range spanning a $15 low (suggesting significant downside risk in a bear case) to a $60 high (reflecting the bulls' view of Briumvi's blockbuster potential).

Sentiment has remained unchanged over the past month, with ratings counts and the average recommendation holding steady at 4.22. This stability suggests analysts are waiting for the Q1 print to either validate their bullish thesis or force a reassessment—there's been no recent wave of upgrades or downgrades, indicating the Street is in a holding pattern. The lack of movement also reflects that much of the Briumvi launch story is already embedded in estimates; analysts need to see execution before committing to further upward revisions.

The $44.57 consensus target sits well above the current price, but the wide dispersion—$45 between high and low—highlights the binary nature of the investment case. Bulls see a clear path to sustained profitability and market share gains in MS, while bears worry about competitive pressures, earnings volatility, and whether the company can translate revenue growth into consistent bottom-line performance. Monday's report will be a key test of which camp has the narrative right.

Part 4: Technical Picture

The Barchart Technical Opinion rates TGTX a 72% Buy, up sharply from 56% Buy a week ago and 8% Buy a month ago—a dramatic strengthening that signals improving technical momentum heading into earnings. The stock has climbed from deeply oversold conditions in early April to a more constructive setup, though it remains below near-term resistance levels.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum has turned positive but lacks conviction, reflecting the stock's recent bounce off lows without a decisive breakout.
• Medium-term (100% Buy): Strong buy signal across the intermediate timeframe suggests the trend has firmly shifted bullish, with the stock reclaiming key moving averages and building a base for further gains.
• Long-term (50% Buy): Moderate buy signal in the longer-term view reflects cautious optimism, as the stock remains well off its 2025 highs and faces overhead resistance from prior peaks.

Trend Characteristics: The signal strength is rated Average with a Strengthening direction, indicating TGTX is in the early stages of a potential trend reversal but has not yet achieved the momentum or breadth to confirm a sustained uptrend—earnings will likely determine whether this nascent strength accelerates or fades.

TGTX is trading at $33.85, positioned above the 50-day ($32.11), 100-day ($31.07), and 200-day ($31.87) moving averages—a constructive longer-term setup—but below the 5-day ($34.23), 10-day ($35.63), and 20-day ($34.92) averages, indicating recent consolidation or pullback from short-term highs. The stock has reclaimed its major moving averages after testing support in the low $30s, but the failure to hold above the 20-day suggests buyers lack conviction ahead of the print. Key resistance sits near $36, the upper bound of the options expected move, while support clusters around $31, the 200-day average and a prior consolidation zone. The technical setup is cautiously supportive—the medium-term trend has turned bullish and the stock is above critical long-term support—but the recent stall below short-term averages and the lack of breakout momentum suggest traders are waiting for earnings to provide direction. A beat could propel TGTX through $36 resistance toward the $44 analyst target zone, while a miss risks a retest of the $31 support level and a breakdown of the nascent uptrend.